Acamprosate calcium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326701

CAS#: 77337-73-6 (calcium salt); 77337-76-9 (free acid).

Description: Acamprosate is a medication used along with counselling in the treatment of alcohol dependence. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcohol withdrawal. Reports indicate that acamprosate works to best advantage in combination with psychosocial support and can help facilitate reduced consumption as well as full abstinence. Until it became a generic in the United States, Campral was manufactured and marketed in the United States by Forest Laboratories, while Merck KGaA markets it outside the US.

Price and Availability


USD 150
USD 650
Ask price

USD 250
USD 950
Ask price

USD 450
USD 1750

Acamprosate calcium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326701
Name: Acamprosate calcium
CAS#: 77337-73-6 (calcium salt); 77337-76-9 (free acid).
Chemical Formula: C10H20CaN2O8S2
Exact Mass:
Molecular Weight: 400.474
Elemental Analysis: C, 29.99; H, 5.03; Ca, 10.01; N, 7.00; O, 31.96; S, 16.01

Synonym: Alcomed; Aotal; Campral; Sobriol; Acamprosate calcium

IUPAC/Chemical Name: Calcium 3-(acetylamino)propane-1-sulfonate


InChi Code: InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2

SMILES Code: O=S(CCCNC(C)=O)([O-])=O.O=S(CCCNC(C)=O)([O-])=O.[Ca+2]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Ho AM, Qiu Y, Jia YF, Aguiar FS, Hinton DJ, Karpyak VM, Weinshilboum RM, Choi DS. Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. Alcohol Clin Exp Res. 2016 May 17. doi: 10.1111/acer.13099. [Epub ahead of print] PubMed PMID: 27184383.

2: Spanagel R, Vengeliene V, Kiefer F. Reply to: Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics. Neuropsychopharmacology. 2016 Feb;41(3):661-2. doi: 10.1038/npp.2015.263. PubMed PMID: 26742861; PubMed Central PMCID: PMC4707840.

3: Mann K, Hoffmann S, Pawlak CR. Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics. Neuropsychopharmacology. 2016 Feb;41(3):659-60. doi: 10.1038/npp.2015.175. PubMed PMID: 26742860; PubMed Central PMCID: PMC4707814.

4: Knudsen HK, Roman PM. The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. J Subst Abuse Treat. 2016 Mar;62:62-7. doi: 10.1016/j.jsat.2015.10.005. Epub 2015 Dec 1. PubMed PMID: 26689318; PubMed Central PMCID: PMC4724483.

5: Ewertowska M, Mikolajczak PL, Okulicz-Kozaryn I, Stacheck B, Murias M, Jodynis-Lieberti J. DIFFERENT RESPONSE OF ANTIOXIDANT DEFENSE SYSTEM TO ACAMPROSATE IN ETHANOL PREFERRING AND NON-PREFERRING RATS. Acta Pol Pharm. 2015 May-Jun;72(3):439-45. PubMed PMID: 26642652.

6: Hajj R, Milet A, Toulorge D, Cholet N, Laffaire J, Foucquier J, Robelet S, Mitry R, Guedj M, Nabirotchkin S, Chumakov I, Cohen D. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease. Sci Rep. 2015 Nov 6;5:16084. doi: 10.1038/srep16084. PubMed PMID: 26542636; PubMed Central PMCID: PMC4635348.

7: Luo Z, Shen Y, Liang M, Miao J, Mei Y, Wang Y, Qin Y. Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. Eur J Pharm Sci. 2015 Nov 15;79:67-72. doi: 10.1016/j.ejps.2015.09.003. Epub 2015 Sep 7. PubMed PMID: 26360834.

8: Nam HW, Karpyak VM, Hinton DJ, Geske JR, Ho AM, Prieto ML, Biernacka JM, Frye MA, Weinshilboum RM, Choi DS. Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. Transl Psychiatry. 2015 Aug 18;5:e621. doi: 10.1038/tp.2015.120. PubMed PMID: 26285131; PubMed Central PMCID: PMC4564571.

9: Doeppner TR, Pehlke JR, Kaltwasser B, Schlechter J, Kilic E, Bähr M, Hermann DM. The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration. J Cereb Blood Flow Metab. 2015 Dec;35(12):2089-97. doi: 10.1038/jcbfm.2015.179. Epub 2015 Jul 29. PubMed PMID: 26219600; PubMed Central PMCID: PMC4671132.

10: Long-term Use of Acamprosate Calcium for Alcoholism: A Review of the Clinical Effectiveness, Safety, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 May 29. Available from PubMed PMID: 26180876.

11: Gueorguieva R, Wu R, Tsai WM, O'Connor PG, Fucito L, Zhang H, O'Malley SS. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. Eur Neuropsychopharmacol. 2015 Oct;25(10):1586-99. doi: 10.1016/j.euroneuro.2015.06.006. Epub 2015 Jun 20. PubMed PMID: 26141511; PubMed Central PMCID: PMC4600651.

12: Plosker GL. Acamprosate: A Review of Its Use in Alcohol Dependence. Drugs. 2015 Jul;75(11):1255-68. doi: 10.1007/s40265-015-0423-9. Review. PubMed PMID: 26084940.

13: Hu W, Morris B, Carrasco A, Kroener S. Effects of acamprosate on attentional set-shifting and cellular function in the prefrontal cortex of chronic alcohol-exposed mice. Alcohol Clin Exp Res. 2015 Jun;39(6):953-61. doi: 10.1111/acer.12722. Epub 2015 Apr 23. PubMed PMID: 25903298.

14: Saitz R. [Acamprosate and naltrexone: similar efficacy for relapse]. Rev Med Suisse. 2014 Dec 17;10(455):2437. French. PubMed PMID: 25752019.

15: Mason BJ. Acamprosate, alcoholism, and abstinence. J Clin Psychiatry. 2015 Feb;76(2):e224-5. doi: 10.4088/JCP.14com09632. PubMed PMID: 25742214.

16: Higuchi S; Japanese Acamprosate Study Group. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry. 2015 Feb;76(2):181-8. doi: 10.4088/JCP.13m08940. PubMed PMID: 25742205.

17: Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015 Jun;110(6):920-30. doi: 10.1111/add.12875. Epub 2015 Mar 17. PubMed PMID: 25664494.

18: Maremmani AG, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D, Dell'Osso L, Maremmani I. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health. 2014 Dec;11(12):12983-96. PubMed PMID: 25590082.

19: Icro Maremmani AG, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D, Dell'Osso L, Maremmani I. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health. 2014 Dec 12;11(12):12983-96. doi: 10.3390/ijerph111212983. PubMed PMID: 25514151; PubMed Central PMCID: PMC4276657.

20: Kraemer KL. Review: In alcohol use disorders, oral naltrexone, 50 mg/d, or acamprosate reduces return to drinking. Ann Intern Med. 2014 Oct 21;161(8):JC7. doi: 10.7326/0003-4819-161-8-201410210-02007. PubMed PMID: 25329224.